Sanofi has announced that its amlitelimab has shown positive results in the treatment of patients 12 years and older with ...
Sanofi has said it will press ahead with regulatory filings for atopic dermatitis (AD) candidate amlitelimab after reporting ...
Amlitelimab is an investigational anti-OX40 ligand monoclonal antibody designed to normalize the overactive immune response in patients with atopic dermatitis.
Sanofi has reported mixed phase 3 data on amlitelimab, further muddying the prospec | Sanofi has reported mixed phase 3 data ...
A Bayesian network meta-analysis comparing four oral JAK inhibitors-upadacitinib, abrocitinib, baricitinib, and ivarmacitinib ...
Shares of Corvus Pharmaceuticals rose after its investigational drug soquelitinib showed positive results in an early-stage trial in atopic dermatitis patients. The stock surged 50% to $12.10 in ...
Nearly 9 in 10 adults and parents of children with plaque psoriasis, atopic dermatitis, and seborrheic dermatitis being ...
How do early-life exposures shape the infant skin microbiome and atopic dermatitis risk? New cohort data reveal key ...
Atopic dermatitis (AD) is a chronic disease that affects an increasing number of children and adults. The skin is dry and ...
If you’re a person of color, finding the right treatment for atopic dermatitis, a common form of eczema, can be challenging. Even though the disease is more prevalent in Black Americans than white ...
There’s no single test that can diagnose atopic dermatitis (the most common type of eczema). Rather, diagnosing this skin condition requires a careful, multifaceted investigation of signs and symptoms ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results